Illumina and Ovation.io launching first-of-kind GLP-1 dataset to accelerate new therapy development
The dataset will be the largest commercially available clinical multiomic dataset for GLP-1 therapies, incorporating whole-genome sequencing and protein expression profiling of 5,000 samples using Illumina's IPP assay that detects 9,500 human proteins per sample.
This initiative addresses significant market needs, as 1 in 8 adults in the US use GLP-1 receptor agonists, but approximately 40% of Type 2 diabetes patients don't respond effectively to these treatments. The dataset will help identify new indications, biomarkers, and drug targets, particularly for non-responsive patients.
Il dataset sarà il più grande disponibile commercialmente per terapie GLP-1, includendo il sequenziamento dell'intero genoma e il profilo di espressione proteica di 5.000 campioni tramite il test IPP di Illumina, che rileva 9.500 proteine umane per campione.
Questa iniziativa risponde a importanti esigenze di mercato, dato che 1 adulto su 8 negli USA utilizza agonisti del recettore GLP-1, ma circa il 40% dei pazienti con diabete di tipo 2 non risponde efficacemente a questi trattamenti. Il dataset aiuterà a identificare nuove indicazioni, biomarcatori e target farmacologici, in particolare per i pazienti non responsivi.
El conjunto de datos será el más grande disponible comercialmente para terapias GLP-1, incluyendo secuenciación del genoma completo y perfilado de expresión proteica de 5,000 muestras mediante el ensayo IPP de Illumina, que detecta 9,500 proteínas humanas por muestra.
Esta iniciativa responde a necesidades significativas del mercado, ya que 1 de cada 8 adultos en EE.UU. usa agonistas del receptor GLP-1, pero aproximadamente el 40% de los pacientes con diabetes tipo 2 no responden eficazmente a estos tratamientos. El conjunto de datos ayudará a identificar nuevas indicaciones, biomarcadores y objetivos terapéuticos, especialmente para pacientes no respondedores.
이 데이터셋은 GLP-1 치료를 위한 상업적으로 이용 가능한 최대 규모의 임상 다중 오믹스 데이터셋으로, Illumina의 IPP 분석법을 사용해 5,000개 샘플의 전장 유전체 시퀀싱 및 단백질 발현 프로파일링을 포함하며, 샘플당 9,500개의 인간 단백질을 검출합니다.
이 이니셔티브는 미국 성인 8명 중 1명이 GLP-1 수용체 작용제를 사용하지만, 약 40%의 2형 당뇨병 환자가 효과적으로 반응하지 않는 중요한 시장 요구를 해결합니다. 이 데이터셋은 특히 비반응 환자를 위한 새로운 적응증, 바이오마커 및 약물 표적을 식별하는 데 도움을 줄 것입니다.
Ce jeu de données sera le plus grand ensemble clinique multiomique disponible commercialement pour les thérapies GLP-1, incluant le séquençage complet du génome et le profilage de l'expression protéique de 5 000 échantillons grâce à l'essai IPP d'Illumina, qui détecte 9 500 protéines humaines par échantillon.
Cette initiative répond à des besoins importants du marché, puisque 1 adulte sur 8 aux États-Unis utilise des agonistes du récepteur GLP-1, mais environ 40 % des patients diabétiques de type 2 ne répondent pas efficacement à ces traitements. Ce jeu de données aidera à identifier de nouvelles indications, biomarqueurs et cibles médicamenteuses, en particulier pour les patients non répondeurs.
Der Datensatz wird der größte kommerziell verfügbare klinische multiomische Datensatz für GLP-1-Therapien sein und umfasst die Ganzgenomsequenzierung sowie die Proteinexpressionsprofilierung von 5.000 Proben mit Illuminas IPP-Assay, der 9.500 menschliche Proteine pro Probe nachweist.
Diese Initiative adressiert bedeutende Marktbedürfnisse, da 1 von 8 Erwachsenen in den USA GLP-1-Rezeptoragonisten verwendet, aber etwa 40 % der Typ-2-Diabetes-Patienten nicht effektiv auf diese Behandlungen ansprechen. Der Datensatz wird helfen, neue Indikationen, Biomarker und Wirkstoffziele zu identifizieren, insbesondere für nicht ansprechende Patienten.
- Partnership creates largest commercially available clinical multiomic dataset from 25,000 GLP-1 therapy patients
- Dataset includes comprehensive analysis: whole-genome sequencing and protein expression profiling of 5,000 samples
- Access to Ovation's extensive biobank of over 1.7 million de-identified samples with longitudinal data
- Integration with Illumina's advanced analysis tools: DRAGEN and Connected Multiomics
- 40% of Type 2 diabetes patients don't respond effectively to GLP-1 receptor agonists
- -
First real-world dataset with integrated clinical and multiomic insights from 25,000 patients treated with GLP-1 therapies
Dataset will advance development of GLP-1 therapies in new indications and accelerate discovery of novel drug targets in patients who are unresponsive to therapies
One in eight adults in
"The power of whole-genome and multiomic insights to impact all diseases is coming into focus, and metabolic disease is a prime example," said Todd Christian, senior vice president of Services, Arrays, and Genomic Access at Illumina. "This collaboration and its novel clinical dataset will be crucial to advancing the next wave of these potential life-changing therapies, and ensuring more patients can benefit from them."
Through a multiyear agreement, Illumina and Ovation are launching an integrated dataset of phenotypic, genomic, and proteomic data from patients treated with GLP-1 therapies, including therapy-responsive and nonresponsive populations. This critical dataset is designed to enable deeper understanding of molecular pathways involved in GLP-1 response, which can unlock new indications where GLP-1 therapies may be effective, as well as new biomarkers and drug targets for patients who do not respond to GLP-1 therapies today.
"We're proud to collaborate with Illumina to develop one of the world's largest WGS omics datasets, supporting the millions of patients with diabetes and obesity," said Marty Miller, chief revenue officer of Ovation. "Through this effort—and for the first time at scale with the inclusion of proteomics—we aim to equip the pharmaceutical industry with the insights needed to better understand the varying effectiveness and side effects of GLP-1 receptor agonists across individual patients."
The initiative leverages end-to-end Illumina NGS technologies to sequence 25,000 whole genomes and to profile the protein expression of 5000 samples, using the Illumina Protein Prep (IPP) assay, which detects 9500 human proteins per sample. The initiative aims to include a longitudinal subset of proteomes from paired samples collected before and after patient exposure to GLP-1 therapy.
IPP enables the discovery of new protein quantitative trait loci (pQTL), which are emerging as a vital tool for drug discovery, linking genetic variation with protein expression data and disease or other phenotypes. The pQTL dataset is processed using Illumina's industry-leading DRAGEN secondary analysis and the newly released Illumina Connected Multiomics for tertiary analysis and visualizations. The data is stored for future large-scale studies in Illumina Connected Analytics.
Ovation is providing samples from its biobank of over 1.7 million de-identified, consented, and tokenized samples, linked to rich, longitudinal phenotypic data.
Ovation announced an original agreement with Illumina in 2024, aimed at addressing challenges in drug development through genomic data solutions. The initial phase of the collaboration focused on creating pilot datasets from patients with liver disease, chronic kidney disease, and patients treated with GLP-1 receptor agonists. The companies plan to explore opportunities to scale the GLP-1 dataset and generate others in the future.
About Illumina
Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as a global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical, and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. To learn more, visit illumina.com and connect with us on X, Facebook, LinkedIn, Instagram, TikTok, and YouTube.
About Ovation
Ovation is a genomic data company committed to unlocking the potential of human genomic data at scale and accelerating precision medicine development. By providing access to high-quality genomic data linked to rich, longitudinal phenotypic data at scale, Ovation allows life sciences researchers to advance drug discovery and development more efficiently. Ovation's cloud-based LIMS and Ovation Research Network, enable a diverse network of clinical laboratories to quickly adopt innovative molecular tests while biobanking and transforming samples to be used for research. For more information about Ovation, visit www.ovation.io
Use of forward-looking statements (Illumina)
This release may contain forward-looking statements that involve risks and uncertainties. Among the important factors to which our business is subject that could cause actual results to differ materially from those in any forward-looking statements are: (i) challenges inherent in developing and launching new products and services, including modifying and scaling manufacturing operations, and reliance on third-party suppliers for critical components; (ii) our ability to manufacture robust instrumentation and consumables; and (iii) the acceptance by customers of our newly launched products, which may or may not meet our and their expectations, together with other factors detailed in our filings with the Securities and Exchange Commission, including our most recent filings on Forms 10-K and 10-Q, or in information disclosed in public conference calls, the date and time of which are released beforehand. We undertake no obligation, and do not intend, to update these forward-looking statements, to review or confirm analysts' expectations, or to provide interim reports or updates on the progress of the current quarter.
Contacts
Investors:
Brian Blanchett
IR@illumina.com
Media:
Christine Douglass
PR@illumina.com
View original content:https://www.prnewswire.com/news-releases/illumina-and-ovationio-launching-first-of-kind-glp-1-dataset-to-accelerate-new-therapy-development-302443981.html
SOURCE Illumina, Inc.
FAQ
What is the size of Illumina's (ILMN) new GLP-1 dataset collaboration with Ovation?
What percentage of Type 2 diabetes patients don't respond to GLP-1 therapies?
How many US adults use GLP-1 receptor agonists?
What is the size of Ovation's biobank used in the ILMN collaboration?
What are the main goals of Illumina's GLP-1 dataset partnership?
